ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)
15.52
+0.31 (2.04%)
Oct 23, 2026, 3:00 PM CST
ChengDu ShengNuo Biotec Revenue
ChengDu ShengNuo Biotec had revenue of 262.98M CNY in the quarter ending June 30, 2026, with 71.62% growth. This brings the company's total for the last twelve months to 911.15M, up 53.21% year-over-year. In the year 2025, ChengDu ShengNuo Biotec had annual revenue of 741.46M with 62.57% growth. That makes ChengDu ShengNuo Biotec the 20,337th largest company in the world by revenue and 3,732nd in China.
Revenue (ttm)
911.15M
Revenue Growth
+53.21%
P/S Ratio
3.75
Revenue / Employee
497.08K
Employees
1,833
Market Cap
3.42B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full ChengDu ShengNuo Biotec breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 741.46M | 285.39M | 62.57% |
| Dec 31, 2024 | 456.07M | 21.05M | 4.84% |
| Dec 31, 2023 | 435.02M | 39.30M | 9.93% |
| Dec 31, 2022 | 395.72M | 9.19M | 2.38% |
| Dec 31, 2021 | 386.53M | 7.76M | 2.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 23.66B |
| Zhejiang Starry Pharmaceutical | 2.46B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.73B |
| Qianjiang Yongan Pharmaceutical | 979.49M |
| PKU HealthCare Corp.,Ltd. | 972.17M |
| Harbin Medisan Pharmaceutical | 805.09M |
| Shandong Wohua Pharmaceutical | 781.18M |
| Shanghai Xiao Fang Pharmaceutical | 537.42M |